nach oben

Erschienen in:

29.12.2016 | Functional Neuroradiology

Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study

verfasst von: Koji Kamagata, Tomoya Nakatsuka, Ryuji Sakakibara, Yohei Tsuyusaki, Tomohiro Takamura, Kanako Sato, Michimasa Suzuki, Masaaki Hori, Kanako K Kumamaru, Tsutomu Inaoka, Shigeki Aoki, Hitoshi Terada

Erschienen in: Neuroradiology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The characteristics of dementia with Lewy bodies (DLB), Alzheimer’s disease (AD) and amnestic mild cognitive impairment (a-MCI) overlap but require different treatments; therefore, it is important to differentiate these pathologies. Assessment of dopamine uptake in the striatum using dopamine transporter (DaT) single-photon emission computed tomography (SPECT) is the gold standard for diagnosing DLB; however, this modality is expensive, time consuming and involves radiation exposure. Degeneration of the substantia nigra nigrosome-1, which occurs in DLB, but not in AD/a-MCI, can be identified by 3T susceptibility-weighted imaging (SWI). Therefore, the aim of this retrospective observational study was to compare SWI with DaT-SPECT for differentiation of DLB from AD/a-MCI.

Methods

SWI data were acquired for patients with clinically diagnosed DLB (n = 29), AD (n = 18), a-MCI (n = 13) and healthy controls (n = 26). Images were analysed for nigrosome-1 degeneration. Diagnostic accuracy was evaluated for DLB, AD and a-MCI compared with striatal dopamine uptake using DaT-SPECT.

Results

SWI achieved 90% diagnostic accuracy (93% sensitivity, 87% specificity) for the detection of nigrosome-1 degeneration in DLB and not in AD/a-MCI as compared with 88.3% accuracy (93% sensitivity, 84% specificity) using DaT-SPECT.

Conclusions

SWI nigrosome-1 evaluation was useful in differentiating DLB from AD/a-MCI, with high accuracy. This less invasive and less expensive method is a potential alternative to DaT-SPECT for the diagnosis of DLB.

Nur mit Berechtigung zugänglich

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12):1863–1872. doi:10.1212/01.wnl.0000187889.17253.b1 CrossRefPubMed

McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien J, Playfer J, Reid W, International Psychogeriatric Association Expert Meeting on DLB (2004) Dementia with Lewy bodies. The Lancet Neurology 3(1):19–28CrossRefPubMed

McKeith I (2007) Dementia with Lewy bodies and Parkinson’s disease with dementia: where two worlds collide. Pract Neurol 7(6):374–382. doi:10.1136/jnnp.2007.134163 CrossRefPubMed

Bajaj N, Hauser RA, Grachev ID (2013) Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 84(11):1288–1295. doi:10.1136/jnnp-2012-304436 CrossRefPubMedPubMedCentral

Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122(Pt 8):1437–1448CrossRefPubMed

Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, Bowtell RW, Auer DP, Gowland PA (2013) Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 81(6):534–540. doi:10.1212/WNL.0b013e31829e6fd2 CrossRefPubMedPubMedCentral

Cosottini M, Frosini D, Pesaresi I, Costagli M, Biagi L, Ceravolo R, Bonuccelli U, Tosetti M (2014) MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology 271(3):831–838. doi:10.1148/radiol.14131448 CrossRefPubMed

Kwon DH, Kim JM, SH O, Jeong HJ, Park SY, ES O, Chi JG, Kim YB, Jeon BS, Cho ZH (2012) Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 71(2):267–277. doi:10.1002/ana.22592 CrossRefPubMed

Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schafer A, Peters AM, Bowtell RW, Auer DP, Gowland PA, Bajaj NP (2012) High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease. Journal of Magnetic Resonance Imaging: JMRI 35(1):48–55. doi:10.1002/jmri.22752 CrossRefPubMed

10.

Cosottini M, Frosini D, Pesaresi I, Donatelli G, Cecchi P, Costagli M, Biagi L, Ceravolo R, Bonuccelli U, Tosetti M (2015) Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol 36(3):461–466. doi:10.3174/ajnr.A4158 CrossRefPubMed

11.

Mueller C, Pinter B, Reiter E, Schocke M, Scherfler C, Poewe W, Seppi K, Blazejewska AI, Schwarz ST, Bajaj N, Auer DP, Gowland PA (2014) Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology 82(19):1752. doi:10.1212/WNL.0000000000000398 CrossRefPubMed

12.

Noh Y, Sung YH, Lee J, Kim EY (2015) Nigrosome 1 detection at 3T MRI for the diagnosis of early-stage idiopathic Parkinson disease: assessment of diagnostic accuracy and agreement on imaging asymmetry and clinical laterality. AJNR Am J Neuroradiol 36(11):2010–2016. doi:10.3174/ajnr.A4412 CrossRefPubMed

13.

Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP (2014) The ‘swallow tail’ appearance of the healthy nigrosome—a new accurate test of Parkinson’s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 9(4):e93814. doi:10.1371/journal.pone.0093814 CrossRefPubMedPubMedCentral

14.

Haller S, Fallmar D, Larsson EM (2015) Susceptibility weighted imaging in dementia with Lewy bodies: will it resolve the blind spot of MRI? Neuroradiology. doi:10.1007/s00234-015-1605-6

15.

Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58(12):1985–1992CrossRefPubMed

16.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34(7):939–944CrossRefPubMed

17.

Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS (2006) Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 33(12):1491–1499. doi:10.1007/s00259-006-0155-x CrossRefPubMed

18.

Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N (2011) SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging 38(4):764–773. doi:10.1007/s00259-010-1664-1 CrossRefPubMed

19.

Wang Y, Butros SR, Shuai X, Dai Y, Chen C, Liu M, Haacke EM, Hu J, Xu H (2012) Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 33(2):266–273. doi:10.3174/ajnr.A2765 CrossRefPubMed

20.

Haller S, Badoud S, Nguyen D, Barnaure I, Montandon ML, Lovblad KO, Burkhard PR (2013) Differentiation between Parkinson disease and other forms of parkinsonism using support vector machine analysis of susceptibility-weighted imaging (SWI): initial results. Eur Radiol 23(1):12–19. doi:10.1007/s00330-012-2579-y CrossRefPubMed

21.

Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL (2007) Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78(11):1176–1181. doi:10.1136/jnnp.2006.110122 CrossRefPubMedPubMedCentral

22.

McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C, Group DLBS (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. The Lancet Neurology 6(4):305–313. doi:10.1016/S1474-4422(07)70057-1 CrossRefPubMed

23.

Antonini A (2007) The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. Neuropsychiatr Dis Treat 3(3):287–292PubMedPubMedCentral

24.

Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, Ferrannini E, Tartaglione B, Defazio G, Rubini G, Livrea P (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Movement Disorders: Official Journal of the Movement Disorder Society 24(14):2097–2103. doi:10.1002/mds.22702 CrossRef

25.

Siepel FJ, Dalen I, Gruner R, Booij J, Bronnick KS, Buter TC, Aarsland D (2016) Loss of dopamine transporter binding and clinical symptoms in dementia with Lewy bodies. Movement Disorders: Official Journal of the Movement Disorder Society 31(1):118–125. doi:10.1002/mds.26327 CrossRef

26.

Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, Duda JE, Stern MB, Mozley D, Katz IR (2005) Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med 46(2):227–232PubMed

27.

Ziebell M, Andersen BB, Pinborg LH, Knudsen GM, Stokholm J, Thomsen G, Karlsborg M, Hogh P, Mork ML, Hasselbalch SG (2013) Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med 54(7):1072–1076. doi:10.2967/jnumed.112.114025 CrossRefPubMed

28.

Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, Burn D, Johnson M, Perry RH, McKeith IG, Ballard C, Perry EK (1999) Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain 122(Pt 8):1449–1468CrossRefPubMed

29.

Perry RH, Irving D, Blessed G, Perry EK, Smith CJ, Fairbairn AF (1990) Dementia in old age: identification of a clinically and pathologically distinct disease category. Adv Neurol 51:41–46PubMed

30.

Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, Zadlo A, Szewczyk G, Zareba M, Sarna T (2008) Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 106(4):1866–1875. doi:10.1111/j.1471-4159.2008.05541.x PubMed

31.

Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT (1999) Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 53(6):1284–1291CrossRefPubMed

32.

McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5):1113–1124CrossRefPubMed

33.

Yamamoto R, Iseki E, Marui W, Togo T, Katsuse O, Kato M, Isojima D, Akatsu H, Kosaka K, Arai H (2005) Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies. Neuropathology 25(3):188–194CrossRefPubMed

34.

Lindboe CF, Hansen HB (1998) The frequency of Lewy bodies in a consecutive autopsy series. Clin Neuropathol 17(4):204–209PubMed

Titel: Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study
verfasst von: Koji Kamagata
Tomoya Nakatsuka
Ryuji Sakakibara
Yohei Tsuyusaki
Tomohiro Takamura
Kanako Sato
Michimasa Suzuki
Masaaki Hori
Kanako K Kumamaru
Tsutomu Inaoka
Shigeki Aoki
Hitoshi Terada
Publikationsdatum: 29.12.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Neuroradiology / Ausgabe 1/2017
Print ISSN: 0028-3940
Elektronische ISSN: 1432-1920
DOI: https://doi.org/10.1007/s00234-016-1773-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study